Trials / Not Yet Recruiting
Not Yet RecruitingNCT07138846
A Study Comparing MRG004A Plus Best Supportive Care Versus Placebo and Best Supportive Care in the Treatment of Patients With Advanced Pancreatic Cancer
A Randomized, Double-blind, Multi-center, Phase III Study of MRG004A Plus Best Supportive Care Versus Placebo and Best Supportive Care in the Treatment of Patients With Advanced Pancreatic Cancer
- Status
- Not Yet Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 231 (estimated)
- Sponsor
- Shanghai Miracogen Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a randomized, double-blind, multi-center, phase III study to evaluate the efficacy and safety, pharmacokinetic profile and immunogenicity of MRG004A in patients with advanced pancreatic cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MRG004A plus best supportive care | MRG004A will be administrated as specified in the protocol. |
| DRUG | Placebo plus best supportive care | Placebo will be administrated as specified in the protocol, following the same dose regimen as MRG004A. |
Timeline
- Start date
- 2026-01-01
- Primary completion
- 2027-06-01
- Completion
- 2027-06-01
- First posted
- 2025-08-24
- Last updated
- 2025-08-24
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07138846. Inclusion in this directory is not an endorsement.